financetom
Business
financetom
/
Business
/
Wendy's Cuts Outlook As International Sales Sizzle, US Growth Stalls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wendy's Cuts Outlook As International Sales Sizzle, US Growth Stalls
Aug 8, 2025 7:38 AM

Wendy’s Company shares are trading higher on Friday.

The company reported second-quarter adjusted earnings per share of 29 cents, beating the analyst consensus estimate of 26 cents. Quarterly sales of $560.929 million (down 1.7% year over year) outpaced the Street view of $560.363 million.

Adjusted Revenues fell 1.3% to $449.6 million.

Also Read: Yum! Brands Opens 871 New Restaurants While Navigating A Slower Quarter

Global systemwide sales totaled $3.7 billion, down 1.8%, while international systemwide sales rose 8.7% across all regions.

“In the second quarter, we continued to expand our global footprint, adding 44 new restaurants, bringing our total additions to 118 in the first half of the year,” said Ken Cook, Interim CEO. “We’re also encouraged by the strong momentum in our International business, which delivered 8.7% systemwide sales growth in the quarter and continues to offer excellent opportunities for expansion.”

The company said it has added 26 net new restaurants and remains on track to deliver full-year net unit growth between 2%-3%.

Operating profit jumped 4.8% to $104.3 million. The increase in operating profit was primarily due to a decrease in the company’s investment in advertising spend, lower reorganization and realignment costs, and lower general and administrative expenses. 

Adjusted EBITDA increased 2.5% to $146.6 million. The increase in adjusted EBITDA was primarily driven by a decrease in the company’s investment in advertising spend, lower general and administrative expense and higher net franchise fees.

The company exited the quarter with cash and equivalents worth $450.512 million.

“In the U.S., we have work to do to improve the overall performance of the business,” Cook added. “We will continue to strengthen relationships with franchisees, improve the effectiveness of our marketing programs, and elevate the customer experience across the system.”

The company announced a quarterly cash dividend of 14 cents per share, payable on September 16.

Outlook

Wendy’s trimmed its fiscal year 2025 adjusted EPS outlook to 82 cents–89 cents (from 92 cents–98 cents), below the 95-cent consensus estimate.

Adjusted EBITDA is expected in the range of $505 million to $525 million, compared with the prior view of $530 million to $545 million.

Global systemwide sales growth is expected to decline in the range of 5%-3% compared with the prior view of flat to 2% decline.

Price Action: WEN shares are trading higher by 2.36% to $10.20 at last check Friday.

Read Next:

McDonald’s Value-First Push Fails To Spur Multiple Expansion: Analyst

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Merck ( MRK ) and Daiichi Sankyo said Wednesday they have dosed the first patient in a phase 2/3 trial assessing the efficacy and safety of investigational drug raludotatug deruxtecan to potentially treat ovarian cancer resistant to platinum-based chemotherapy. The second phase of the study is being done to establish the dose of...
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Wednesday it has started a phase 2 study of ALTO-203 in major depressive disorder patients. Alto said it expects to enroll about 60 adult participants with MDD and anhedonia, with top-line data expected in H1 of 2025. The company said ALTO-203 showed a favorable tolerability profile across...
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Asensus Surgical ( ASXC ) shares jumped more than 28% in recent trading after the company said Wednesday that it has entered into a non-binding letter of intent with medical technology company KARL STORZ for a potential acquisition of Asensus. Asensus said that the letter of intent includes the proposal to acquire all...
Factbox-US, Canadian companies kick off 2024 with layoffs
Factbox-US, Canadian companies kick off 2024 with layoffs
Apr 3, 2024
(Reuters) -Companies in the United States and Canada have kicked off 2024 with thousands of job cuts across sectors, signaling that the spate of layoffs seen in 2023 could persist as they scramble to rein in costs. While hopes of a soft landing have grown in recent months, companies continue to be cautious as the outlook on rate cuts by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved